iShares US Aerospace & Defense ETF vs Vaxcyte Inc. Common Stock — how do they compare? iShares US Aerospace & Defense ETF trades at $203.99 (market cap $11.96B), while Vaxcyte Inc. Common Stock trades at $67.27 (market cap $10.51B). The key difference: iShares US Aerospace & Defense ETF and Vaxcyte Inc. Common Stock are close in size by market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, iShares US Aerospace & Defense ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares US Aerospace & Defense ETF for 24 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| ITA | PCVX | |
|---|---|---|
Market Cap | $11.96B | $10.51B |
Volume | 750,577 | 2,644,694 |
Sector | Sector/Thematic | Health |
52-Week High | $253.22 | $73.82 |
52-Week Low | $198.23 | $40.32 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | — | $9.14B |
Signals from Pluang's Aura AI — not financial advice
ITA trades at $204.00, down 0.99% with bearish technical signals from moving averages. The ETF shows neutral oscillators but faces selling pressure with RSI at oversold levels. Recent corporate actions include a 1:3 stock split scheduled for November 2026 and a $0.25 dividend payment in September 2026. Defense sector momentum remains strong with multiple contract wins and geopolitical tensions driving demand.
The defense sector outlook appears favorable with increased government spending and geopolitical tensions, though ITA faces technical headwinds. Key risks include defense budget volatility and geopolitical resolution. Analyst sentiment remains mixed with the ETF positioned to benefit from ongoing military modernization programs and replenishment of defense inventories.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
iShares U.S. Aerospace & Defense ETF seeks to track U.S. companies in the aerospace and defense sector. Its holdings include manufacturers of commercial and military aircraft, defense systems, and related equipment.
Read more on ITA →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →